AC

Asymmetry Capital Management

North America, California, United States, San Francisco

Description

Asymmetry Capital Management is a San Francisco-based alternative asset management firm.

Investor Profile

Asymmetry Capital Management has made 5 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series C (40%)
  • Post Ipo Equity (20%)
  • Seed (20%)
  • Series D (20%)

Country Focus

  • United States (40%)
  • Switzerland (20%)
  • Hong Kong (20%)
  • Denmark (20%)

Industry Focus

  • Biotechnology
  • Medical
  • Medical Device
  • Cryptocurrency
  • Gaming
  • Health Care
  • Health Diagnostics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Asymmetry Capital Management frequently co-invest with?

CA
North America, Massachusetts, United States, Boston
Co-Investments: 2
New Leaf Venture Partners
North America, New York, United States, New York
Co-Investments: 2
Eventide
North America, Massachusetts, United States, Boston
Co-Investments: 2
DC
North America, Illinois, United States, Chicago
Co-Investments: 2
Northpond Ventures
North America, Maryland, United States, Bethesda
Co-Investments: 2
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 2
OUP (Osage University Partners)
North America, Pennsylvania, United States, Bala Cynwyd
Co-Investments: 2
Soleus Capital
North America, Connecticut, United States, Greenwich
Co-Investments: 3
Sands Capital Ventures
North America, Virginia, United States, Arlington
Co-Investments: 2
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 2

What are some of recent deals done by Asymmetry Capital Management?

Anichess

Hong Kong, Hong Kong Island, Hong Kong

Anichess develops a decentralized chess game.

CryptocurrencyGaming
SeedJun 22, 2023
Amount Raised: $1,500,000
MoonLake Immunotherapeutics

Zug, Zug, Switzerland

MoonLake Immunotherapeutics is a clinical-stage biopharmaceuticals company.

Biotechnology
Post Ipo EquityApr 6, 2022
Amount Raised: $115,000,000
Dice Therapeutics

San Francisco, California, United States

Dice Therapeutics is a clinical-stage biopharmaceutical company that makes medicines for chronic autoimmune and inflammatory diseases.

BiotechnologyMedicalMedical Device
Series CAug 24, 2021
Amount Raised: $60,000,000
Dice Therapeutics

San Francisco, California, United States

Dice Therapeutics is a clinical-stage biopharmaceutical company that makes medicines for chronic autoimmune and inflammatory diseases.

BiotechnologyMedicalMedical Device
Series CJan 8, 2021
Amount Raised: $80,000,000
Galecto

Copenhagen, Hovedstaden, Denmark

Galecto is a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer.

BiotechnologyHealth CareHealth Diagnostics
Series DSep 25, 2020
Amount Raised: $64,000,000